Dr Christopher Nelson | aVP, Vaccine Public Affairs, Dengue
Sanofi Pasteur

Dr Christopher Nelson, aVP, Vaccine Public Affairs, Dengue, Sanofi Pasteur

Christopher B. Nelson, PhD MPH, aVP, Vaccine Public Affairs – Dengue.
Dr. Nelson has worked in both the public and private sectors with a focus on field and clinical research and new vaccine policy and programs for over 30 years.
Before joining the Dengue Company at Sanofi Pasteur in 2014, Dr. Nelson worked as founding Director of the Coalition against Typhoid (CaT) Secretariat at the Sabin Vaccine Institute and before this as Senior Director at Merck Vaccines Division (MSD ex-USA) where he led Merck’s contributions to the accelerated launch of rotavirus and HPV vaccines in GAVI and other countries.
From 1997 to 2006, Dr. Nelson worked on surveillance systems, vaccine policy and introduction strategies in low- and middle-income countries while at the World Health Organization (WHO) in Geneva, Switzerland. At WHO, his responsibilities included developing vaccine-preventable-disease surveillance systems, clinical research, and technical strategies and policy in support of the accelerated adoption of HepB, Hib, meningococcal, rotavirus, and other vaccines in Africa, the Middle East and Asia.
Dr. Nelson began his public health career working with a focus on the development of primary health care systems and demographic surveillance in the shanty towns and mountain communities of Peru during the 1980’s


DC Co-conference Day 2 April 4 @ 11:40

Can we use moderately effective vaccines for safe public use? Using Dengue as an example

back to speakers